GlassScriptPhysician profile
Wendy Sanders
NPI 1679315980
$3,661.95
in general payments reported to CMS, 2019-2025
28 companies · $2,718 in 2025
The $2,718 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $944 · 2025: $2,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,577 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,576.95 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $634.61 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $500.68 | 2024-2025 | Korlym |
| Amgen INC. | $391.03 | 2024-2025 | Evenity, Tepezza |
| Madrigal Pharmaceuticals | $382.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $326.06 | 2024-2025 | |
| Mannkind Corporation | $300.99 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $136.51 | 2025 | Isturisa |
| Kyowa Kirin, INC. | $100.47 | 2024-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $99.53 | 2024-2025 | |
| Novo Nordisk INC | $94.38 | 2024-2025 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $90.99 | 2024-2025 | Strensiq |
| Radius Health, INC. | $77.27 | 2025 | Tymlos |
| Tandem Diabetes Care, INC. | $72.98 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $72.78 | 2025 | Yorvipath |
| Abbott Laboratories | $57.18 | 2025 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $47.81 | 2025 | |
| Sanofi-Aventis U.S. LLC | $47.47 | 2024-2025 | |
| Sandoz INC. | $34.14 | 2024 | |
| Acella Pharmaceuticals, LLC | $31.04 | 2025 | NP Thyroid 60 |
| Pharmacosmos Therapeutics INC. | $24.89 | 2025 | Monoferric |
| Shield Therapeutics INC | $24.43 | 2025 | |
| Astellas Pharma US INC | $23.04 | 2025 | Veozah |
| Beta Bionics, INC. | $21.22 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Esperion Therapeutics, INC. | $17.03 | 2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $16.34 | 2025 | Unithroid |
| Verity Pharmaceuticals INC. | $15.75 | 2025 | Tlando |
| Lilly USA, LLC | $13.86 | 2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $7.25 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.